Overview
Dexamethasone (0.4mg) Ophthalmic Insert.
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-10-01
2022-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) with or without iStent/Hydrus/Goniotomy when placed in the lower punctum compared to the upper punctum.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Iworks Laser and Vision CenterCollaborator:
Ocular Therapeutix, Inc.Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Criteria
Inclusion Criteria:- Subjects will be eligible for study participation if they:
Are planning to undergo non-complicated CCI CE/PCIOL in one or both eyes with or without
iStent/Hydrus/Goniotomy Are willing and able to comply with clinic visits and study related
procedures Are willing and able to sign the informed consent form
Exclusion Criteria:
- Have active infectious systemic disease Have active infectious ocular or extraocular
disease Have unobstructed nasolacrimal duct in the study eye(s) (dacryocystitus) Have
known hypersensitivity to dexamethasone or are a known steroid responder Have a
history of ocular inflammation or macular edema Are currently being treated with
immunomodulating agents in the study eye(s) Are currently being treated with
immunosuppressants and/or oral steroids Are currently being treated with
corticosteroid implant (i.e. Ozurdex) Have a history of herpes simplex virus keratitis
or present active bacterial, viral, or fungal keratitis in either eye Have a history
of complete punctal occlusion in one or both punctum Currently use topical ophthalmic
steroid medications Are unwilling or unable to comply with the study protocol Are
determined by the Investigator to not be included for reasons not already specified
(e.g., systemic, behavioral, or other ocular disease/abnormality) or if the health of
the subject or the validity of the study outcomes may be compromised by the subject's
enrollment